Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

INTRODUCTION: We assessed effects of AZD7442 (tixagevimab/cilgavimab) on deaths from any cause or hospitalizations due to coronavirus disease 2019 (COVID-19) and symptom severity and longer-term safety in the TACKLE adult outpatient treatment study. METHODS: Participants received 600 mg AZD7442 (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Hobbs, F. D. Richard, Montgomery, Hugh, Padilla, Francisco, Simón-Campos, Jesus Abraham, Kim, Kenneth, Arbetter, Douglas, Padilla, Kelly W., Reddy, Venkatesh Pilla, Seegobin, Seth, Streicher, Katie, Templeton, Alison, Viani, Rolando M., Johnsson, Eva, Koh, Gavin C. K. W., Esser, Mark T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581960/
https://www.ncbi.nlm.nih.gov/pubmed/37751015
http://dx.doi.org/10.1007/s40121-023-00861-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581960/
https://www.ncbi.nlm.nih.gov/pubmed/37751015
http://dx.doi.org/10.1007/s40121-023-00861-7

Ejemplares similares